Voyager Therapeutics (NASDAQ: VYGR) grants SVP 100,000 stock options

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. reported that its SVP and General Counsel, Gregory L. Shiferman, received a grant of stock options for 100,000 shares of common stock on January 6, 2026. The options have an exercise price of $4.02 per share and were issued under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The options vest over four years, with one quarter of the underlying shares vesting on the one-year anniversary of the grant date and the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued employment. Following this grant, he holds 100,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shiferman Gregory L.

Role SVP and General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	100,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 shares (Direct)

Footnotes (1)

1. This stock option was granted pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shiferman Gregory L.

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.02	01/06/2026		A		100,000(1)		(2)	01/06/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. This stock option was granted pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.

2. The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.

	/s/ Gregory L. Shiferman	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Voyager Therapeutics (VYGR) report for Gregory L. Shiferman?

Voyager Therapeutics reported that SVP and General Counsel Gregory L. Shiferman received a grant of stock options for 100,000 shares of common stock on January 6, 2026.

What is the exercise price of the new Voyager Therapeutics (VYGR) stock options?

The stock options granted to Gregory L. Shiferman have an exercise price of $4.02 per share.

How do the newly granted Voyager Therapeutics (VYGR) stock options vest?

The options vest over four years: 1/4 of the shares vest on the one-year anniversary of the grant date, and an additional 1/48 of the shares vest at the end of each subsequent month for three years, subject to continued employment.

Under which plan were the Voyager Therapeutics (VYGR) options granted to Gregory L. Shiferman?

The stock options were granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.

What is Gregory L. Shiferman’s role at Voyager Therapeutics (VYGR)?

Gregory L. Shiferman serves as Senior Vice President (SVP) and General Counsel of Voyager Therapeutics, Inc.

How many Voyager Therapeutics (VYGR) stock options does Gregory L. Shiferman hold after this grant?

After the reported grant, Gregory L. Shiferman beneficially owns 100,000 stock options directly.